Nyxoah S.A. (NYXH) - Year-over-year earnings per share growth for the last twelve months

The quarterly EPS gap clearly demonstrates the profit recovery trend, where the current figure stands at 72.80. Nyxoah S.A. (NYXH) is implementing neurostimulators to combat apnea, expanding its presence in the sleep medicine segment. Manufacturing processes are delegated to contractors, while services are handled via outsourcing. The Belgian origin and humanitarian profile of the business guarantee stability and an absence of geopolitical risks.
NYXH (nyxoah.com): analytical breakdowns and indicator data

Investors are assessing the resilience of Nyxoah S.A. (NYXH) through its ability to generate a stable cash flow. This indicator measures the dynamics of net earnings per share, comparing the current quarterly result with the same period last year. Analyzing the percentage growth of earnings per share per quarter reveals the actual efficiency of cost management. For a company in the sleep apnea treatment sector, this is a critical marker of competitiveness when vying for insurance contracts. A positive trend confirms technological superiority over alternative therapy methods.